Tesamorelin
Also known as Egrifta, TH9507
Tesamorelin is an FDA-approved GHRH analog specifically studied and approved for reducing visceral abdominal fat. It's more stable than native GHRH and produces robust GH/IGF-1 increases with particularly strong effects on belly fat reduction.
How it works
Stabilized GHRH analog that binds GHRH receptors with high affinity, stimulating GH release and downstream IGF-1 production. Superior stability vs sermorelin due to trans-3-hexenoic acid modification.
Benefits
- FDA-approved for visceral fat reduction
- Strong reduction in abdominal/visceral fat
- Significant GH and IGF-1 elevation
- Improved lipid profiles
- Cognitive benefits (studied for MCI/Alzheimer's prevention)
- Body composition improvements
Dosing
1000–2000 mcg · Once daily
FDA-approved dose is 2mg daily. Research/biohacker protocols often use 1–2mg daily.
Ranges reflect commonly cited research protocols, not a prescription. Dose with a licensed provider.
Reconstitution
2mg vial with 2mL BAC water = 1mg/mL
Helix’s free reconstitution calculator gives you the exact draw volume → get the app
Common stacks
Reported side effects
- Injection site reactions
- Water retention
- Joint pain
- Carpal tunnel
- Glucose intolerance possible
Who it’s for
Those focused on visceral fat reduction, metabolic health, or wanting a research-backed GHRH analog with FDA approval data. Intermediate users.
Track Tesamorelin in Helix
Dose reminders, reconstitution math, vial tracking, and AI guidance — free on iOS.
Download free